Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Faron Pharmaceuticals

2.02 EUR

-3.35 %

5,523 following

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

-3.35 %
-13.68 %
-11.01 %
-26.01 %
-20.47 %
-9.62 %
-40.24 %
-34.84 %
-41.95 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
238.45M EUR
Turnover
678.29K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Accumulate
Target price
Updated
24.10.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 24.10.2025

Latest extensive report

Released: 23.08.2022

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.3.
2026

Annual report '25

30.3.
2026

General meeting '26

26.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Faron ESMO 2025
Webcast

Faron ESMO 2025

Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients with an 85% ORR and a 45% CR rate, bolstered by pharmacodynamic insights.

Faron Pharmaceuticals
Forum discussions
I rarely write these days, but there are starting to be a bit too many posts in this thread that bring very little value to the discussion. It makes it difficult to follow the thread, as this place has historically offered more added value than many other meme-type sources. Please...
6 hours ago
by NEA
56
This thread has gone completely off the rails. Usernames are bickering with each other with sandbox-level comments. All sorts of announcements are being copy-pasted, sometimes AI-generated content without checking any facts, etc. etc. Sad.
8 hours ago
by Peetuli
41
In my opinion, the pieces are starting to fall into place here: -Lind sells his shares as before, prior to the directed issue -Faron intends to proceed to the next phase on its own, and money is needed for that -Faron announces a CFO change completely out of the blue, because a more...
7 hours ago
16
It’s not possible to know exactly when Timo’s sales occurred, sometime between 20.10. and yesterday’s 3.12. disclosures. He might have taken quick profits of, say, 20% with that stack of over 100k shares at the 2.40 price level in early November.
8 hours ago
9
Here’s a quick Excel analysis of the development of Syrjälä’s holdings. At the turn of November-December, the ownership stake was still over 15%, even though he/she had previously divested some of his/her shares, but only the latest HCM dilution lowered the ownership stake below ...
7 hours ago
by Mahtiponti
7
You can find that information in the stock exchange release, if you would just bother to read it amidst all your chatter:
8 hours ago
6
Well, that shows the share ownership on 20.10.2025, and the ownership % does not take into account the company’s own shares. You should sometimes read things from stock exchange releases before you each start guessing/posting your findings. Here is information about the number of...
8 hours ago
4
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.